Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Deffered Revenue: 2019-2024

Historic Non-Current Deffered Revenue for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $26.2 million.

  • Nurix Therapeutics' Non-Current Deffered Revenue fell 49.18% to $15.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $15.2 million, marking a year-over-year decrease of 49.18%. This contributed to the annual value of $26.2 million for FY2024, which is 41.79% down from last year.
  • According to the latest figures from FY2024, Nurix Therapeutics' Non-Current Deffered Revenue is $26.2 million, which was down 41.79% from $45.0 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Non-Current Deffered Revenue ranged from a high of $60.7 million in FY2020 and a low of $26.2 million during FY2024.
  • In the last 3 years, Nurix Therapeutics' Non-Current Deffered Revenue had a median value of $36.0 million in 2022 and averaged $35.7 million.
  • In the last 5 years, Nurix Therapeutics' Non-Current Deffered Revenue spiked by 70.02% in 2020 and then tumbled by 41.79% in 2024.
  • Nurix Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $60.7 million in 2020, then fell by 2.74% to $59.0 million in 2021, then slumped by 39.05% to $36.0 million in 2022, then rose by 25.15% to $45.0 million in 2023, then crashed by 41.79% to $26.2 million in 2024.